Creating a new thread to capture media updates and significant...

Creating a new thread to capture media updates and significant advances in our product development. Are you across how the science behind ARG-007 works and the potential positive outcomes?

Argenica Therapeutics developing drugs for brain recovery. Why? The sentiment reported every 19 minutes someone has a stroke.

In 2019 that was 13 million people globally. During a stroke, the lack of oxygen caused by the blockage of blood vessels kills 1.9 million brain cells per minute.



The medical interventional methods available to stroke patients are limited and focus on removing the clot chemically or mechanically. Doctors employ anticoagulants and thrombolytic drugs to break down the clot causing the blockage. Oftentimes they resort to physically removing the clot with a catheter or in some cases, surgery.

Restricting the amount of damage to the brain is challenging and time sensitive. Only 35% of all patients with acute stroke arrive at hospital within the critical 4.5 hour time frame for treatment. Failure to treat stroke within this narrow time frame is associated with poor clinical outcomes and long term issues. Strokes can affect the functioning of almost any system within the body, depending on where in the brain the stroke occurs.There is currently no neuroprotective drug on the market that can be administered to slow the effects of hypoxia in the brain.

Pioneering the vision to fill this critical market gap is pre-clinical drug development company Argenica Therapeutics. Their neuroprotective compound, rich in their namesake arginine peptides, is emerging as a promising solution to this complex problem.

The ARG-007 compound was developed by researchers at the University of Western Australia and the Perron Institute for Neurological and Translational Science and has demonstrated improved outcomes in pre-clinical models of stroke.

These preliminary results spurred the incorporation of Argenica in November 2019 to develop and commercialise the drug.

Why could Argenica become a game changer in the medical industry with huge share price appreciation?

1. ARG-007 has been developed by leading researchers at The University of Western Australia and the Perron Institute. Check out the experience. I've never seen so much experience with directors and research team on a 12 million market capitalization company. This has the potential to move.



2. The current treatment options for Stroke remain limited to restoring blood flow through clot removal by tPA thrombolysis and mechanical thrombectomy.Despite considerable research, there are currently no marketed drugs capable of protecting the brain from damage following stroke.This means there is an urgent unmet need and priority to search for widely applicable and effective neuroprotective drugs for stroke patients.

Over the last 6 years Argenica’s lead scientists have been working with ARG-007 to determine its ability to reduce brain tissue death following stroke.

We are hopeful that we have developed a neuroprotective drug that can be administered in the field by paramedics, and used in conjunction with endovascular therapy (thrombolysis/thrombectomy) to improve neuroprotective outcomes, and importantly increase the number of patients amenable to thrombolysis and thrombectomy.

We have accumulated a comprehensive body of published preclinical studies demonstrating neuroprotective efficacy of ARG-007 in multiple models of stroke and other CNS models of injury. In stroke, neuronal excitotoxicity, caused by increased extracellular glutamate, causes neuronal calcium overload and mitochondrial dysfunction.

In several, well-established, in vitro models of stroke we demonstrated that ARG-007 is neuroprotective, in a dose-dependent manner.ARG-007 Reduces Brain Tissue DeathPotent neuroprotection is observed following a single intravenous (IV) administration of ARG-007 several hours after stroke onset (mimicking the clinical situation) in three different in vivo models of stroke.

Importantly, ARG-007 provided greater than 60% preservation of brain for at least 28 days post-stroke and reliably improved function preclinically.

The ability of ARG-007 to slow the progression of brain injury (infarct) and preserve brain cells would increase the number of patients suitable for thrombolyisis/thrombectomy, as well as maximising the amount of available salvageable brain tissue at the time of restoring blood flow.Based on MRI studies we have demonstrated that ARG-007 can significantly slow infarct growth and preserve salvageable penumbral tissue following MCAO stroke.

The ideal stroke therapeutic would target multiple parts of the ischaemic and excitotoxic cascade of events, as drugs affecting a single target in this cascade have not previously been effective in providing neuroprotection in stroke patients.

ARG-007 has a plurifunctional mechanism of action, affecting neuronal excitotoxicity, calcium influx and mitochondrial dysfunction, and reducing the activation of damaging proteolytic enzymes which greatly enhances its neuroprotective potential and translational clinical effectiveness.

3. Market capitalization of $12m with circa $8 cash on hand. Enterprise value only valued at a tiny $6.6m. If your reading this then you have done your research and found this stock before the potential market has found it. Perfect time to accumulate.



4. Tightly held capital structure.

- Director supported 19%
- Researchers team supported 3.7%
- Perron Institue 4.7%
- University of Western Australia 5.4%
- Sophisticated investors 21%

Thus holding 53% of shares on allocation with accumulation of remaining 43% occuring at the moment explains why basically zero shares for sale and only buyers.


5. Untapped opportunity by 2030 estimated to be $183 billion.



6. ARG-007 Development Road Map progressing short term. The next few months will be game changing for AGN and early movers.



7. Share price appreciation on current Enterprise value of only $6 million could be potentially x 10 in the short term even before considering announcements. imho.